Automation funded Adaptyv Bio has just secured a $46.6M Series A to scale automated wet-lab R&D for AI-driven protein design, signaling a strong appetite for scalable collaboration and tooling partnerships in high-throughput protein research.

Public API expansion Recent integrations with Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling, plus a shipped public API, create multiple cross-sell and partner opportunities with downstream platforms in computational biology and laboratory informatics.

London expansion New facilities and offices in London and Lausanne indicate geographic growth and potential access to European biotech clusters, enabling regional sales motions for wet-lab automation, reagents, and service contracts.

Revenue signals Reported December 2024 revenue of $2.6M alongside current funding, suggesting a growth trajectory; targeted outreach to scale collaborations, licensing, and contract research arrangements could yield strategic revenue streams.

Platform leverage With a focus on a next-gen protein foundry and a suite of design-to-test capabilities, there is an opportunity to position complementary tools, data services, and AI-assisted design platforms as integral parts of Adaptyv's automated ecosystem.